This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

The prognosis in myasthenia gravis is very variable. The use of immunosuppressive drugs has steadily improved outcome in recent years.

Remission or substantial improvement can be expected in 80% of patients. For those with associated thymoma, the 5 year survival is approximately 30 %.

Patients with older age of onset and comorbidities, including other associated autoimmune diseases, typically have a poorer prognosis.

Reference

  1. Hansen JS, Danielsen DH, Somnier FE, et al. Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve. 2016 Jan;53(1):73-7.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page